Search the Newsreel

Roivant Sciences (ROIV) Is Up 7.2% After Narrower Net Loss Despite Lower Quarterly Revenue

Roivant Sciences (ROIV) reported a narrower net loss in Q1 2026, reaching US$189.84 million compared to US$223.36 million a year earlier, despite a dip in revenue to US$1.44 million. This improvement in net loss and basic loss per share suggests progress in efficiency and …

Roivant Sciences Ltd (ROIV) Earnings Forecast: Future EPS & Revenue Growth Estimates

Citi Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $46

Citi has reiterated its Buy rating on Roivant Sciences (ROIV.US) and increased its target price to $46. This positive adjustment suggests increased confidence from Citi in the company's future performance.

Is Roivant Sciences’ (ROIV) Cost Discipline Offsetting Slower Revenue Enough to Refresh Its Story?

Roivant Sciences reported past first-quarter 2026 results, with sales of US$1.44 million versus US$2.17 million a year earlier and a narrower net loss of US$189.84 million, reducing basic loss per share from US$0.33 to US$0.26. The combination of lower revenue yet improved loss per …

Is Roivant Sciences (ROIV) Overvalued On First Quarter Results?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Roivant Sciences Stock Is In Focus After First Quarter Results Roivant Sciences (NasdaqGS:ROIV) is in focus after reporting first quarter results for the …

Roivant Sciences Ltd. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:ROIV) 2026-08-06

This article announces the publication of Roivant Sciences Ltd.'s 2026 Q1 earnings call presentation. The company reported an EPS of -$0.34, beating estimates by $0.02, and revenue of $1.44M, which missed expectations by $897.33K, representing a 33.55% year-over-year decrease. The slide deck provides details …

Roivant Sciences (ROIV) Stock Rally Leans On Cash As Losses Persist

Roivant Sciences (ROIV) stock has rallied despite recent losses, driven by its strong cash position of nearly US$4.0 billion and a promising late-stage autoimmune pipeline. While the company recorded a net loss of US$189.84 million in Q1 2027, investors are focusing on pipeline milestones …

Roivant Sciences Ltd (ROIV) Stock News Today

Roivant Sciences Ltd. 2026: Revenue $1.44M, EPS ($0.26) — 10-Q Summary

Roivant Sciences Ltd. (ROIV) reported its 2026 quarterly results, showing revenue of $1.44 million and a diluted loss per share of ($0.26). This represents a decrease in revenue and an improvement in diluted EPS compared to the prior-year quarter. The company also highlighted pipeline …

Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $39.73, Implies 15% Upside

Roivant Sciences Ltd. (ROIV) has seen its average 12-month price target raised from $38.91 to $39.73 by 11 analysts, with forecasts ranging from $34 to $50 per share. This new target implies a potential upside of approximately 15% based on the August 5th closing …

Earnings call transcript: Roivant misses Q1 2026 EPS as pipeline build accelerates

Roivant Sciences reported a wider-than-expected first-quarter loss, with EPS of -$0.75 against an analyst forecast of -$0.60, as the company continued heavy spending on R&D and commercial preparation. Despite the miss, management framed the period as a "calm before the storm," anticipating a "jam-packed …

Roivant Sciences Releases Q1 2026 Financial Results

Roivant Sciences Ltd. reported a narrowed Q1 2026 diluted EPS loss of -$0.26, a 21.2% improvement year-over-year, despite a net loss of $189.8M and a revenue decline to $1.4M. The clinical-stage biopharmaceutical company continues to focus on advancing its drug pipeline, with Wall Street …

Roivant Sciences earnings beat by $0.04, revenue fell short of estimates

Roivant Sciences (NASDAQ: ROIV) reported second-quarter earnings per share of $-0.260, surpassing analyst estimates by $0.04. However, the company's revenue of $1.44 million fell short of the consensus estimate of $2.32 million. Despite the revenue miss, Roivant Sciences' stock has shown strong performance, increasing …

Roivant Sciences Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2026

Roivant Sciences Ltd. reported its financial results for the first quarter ended June 30, 2026. The company experienced a decrease in sales to USD 1.44 million from USD 2.17 million in the prior year. Despite lower sales, the net loss narrowed to USD 189.84 …

Roivant Sciences Q1 2027 Earnings Call Transcript

Roivant Sciences held its Q1 2027 earnings call, highlighting significant progress and an exciting pipeline for the coming year. The company is on track for the late September launch of brepocitinib for dermatomyositis and has initiated a Phase III study for cutaneous sarcoidosis. Roivant …

Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q1 Revenue $1.4M, vs. FactSet Est of $2.1M

Roivant Sciences Ltd. reported Q1 revenue of $1.4 million, which fell short of FactSet's estimated $2.1 million. This financial update indicates that the biopharmaceutical company's revenue performance for the quarter did not meet analyst expectations. The article provides a snapshot of the company's recent …

Roivant Sciences (NASDAQ: ROIV) details $771.6M Moderna settlement windfall

Roivant Sciences (NASDAQ: ROIV) reported a net loss of $290.6 million for the quarter ended June 30, 2026, driven by increased research and development expenses. The company's liquidity was significantly bolstered by a $771.6 million litigation settlement receivable from Moderna, which was collected in …

Roivant Sciences Ltd. (ROIV) Tops Q1 EPS by 4c

Roivant Sciences Ltd. (ROIV) reported its Q1 earnings, beating analyst EPS estimates by $0.04 with a reported EPS of ($0.26) against an estimated ($0.30). However, the company's revenue for the quarter came in at $1.44 million, falling short of the consensus estimate of $2.32 …

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

(ROIV) and the Role of Price-Sensitive Allocations

This article provides an AI-generated analysis of Roivant Sciences Ltd. (NASDAQ: ROIV), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also …

Roivant Sciences Ltd. Revenue Breakdown – NASDAQ:ROIV

This article provides a brief overview of Roivant Sciences Ltd.'s revenue breakdown for the last fiscal year. The company generated $8.26 million USD, with its primary revenue stream coming from the "Medicines and Technologies" segment. The United Kingdom was the largest regional contributor to …

Roivant Sciences Ltd (ROIV) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Roivant Sciences Ltd (ROIV)'s financial health, indicating a current financial score of 6.75, ranking 131 out of 155 in the Pharmaceuticals industry. The company's financial status is described as robust, with low operating efficiency. Latest quarterly revenue decreased …

BofA raises Roivant Sciences stock price target on trial outlook

Roivant Sciences Ltd (ROIV) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Roivant Sciences Ltd (ROIV), stating its current valuation score is 7.28, ranking 132 out of 155 in the Pharmaceuticals industry. The P/E ratio is reported as -79.90, which is below its recent high and above its recent …

Roivant Sciences (ROIV) Expected to Post Quarterly Earnings on Thursday

Roivant Sciences (ROIV) president sells 200k shares after exercising options

Eric Venker, President of Roivant Sciences (ROIV) and CEO of Immunovant, exercised 200,000 stock options at $3.85 per share on July 27, 2026. Following this exercise, he sold all 200,000 common shares at a weighted average price of $34.95 per share, under a Rule …

Roivant Sciences(ROIV.US) Officer Sells US$6.99 Million in Common Stock

One of Roivant Sciences (ROIV.US) officers, Andrew Pearlman, recently sold 700,000 shares of common stock for a total of $6.99 million. This transaction occurred on July 26

Form DEF 14A Roivant Sciences Ltd. For: 29 July By Investing.com

This article announces the filing of Form DEF 14A by Roivant Sciences Ltd. on July 29th, as reported by Investing.com. It also includes standard disclaimers about the high risks involved in trading financial instruments and cryptocurrencies. The content emphasizes that data provided is not …

Roivant Sciences Ltd (ROIV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Roivant Sciences Ltd (ROIV), focusing on its stock price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 28, 2026, ROIV's price momentum score is 2.69, and it is trading between …

ROIV|Roivant Sciences Ltd|Price:34.028|Chg%:-0.692

Roivant Sciences Ltd (ROIV) shows strong fundamentals and high growth potential, according to TradingKey analysis. The stock is considered fairly valued and has a high institutional ownership, with multiple analysts giving it a "Buy" rating and a target price of 37.53. Despite sideways trading …

Roivant Sciences (ROIV) affiliate files to sell 200,000 common shares after option exercise

An affiliate of Roivant Sciences (ROIV), Eric Venker, has filed a Form 144 notice to sell 200,000 common shares obtained from an option exercise granted on April 20, 2022, with a proposed sale date of July 27, 2026. This filing also discloses two prior …

Roivant Sciences Ltd (ROIV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Roivant Sciences Ltd (ROIV) for FY2025Q1. It details the company's revenue of $55.13 million, with all of it attributed to the "VTAMA" business segment and originating from the United States. The report indicates a 0.00% proportion from …

Roivant Sciences Ltd. Revenue Breakdown – TRADEGATE:87S

Roivant Sciences Ltd. (TRADEGATE:87S) generated €7.15 million in revenue last year, primarily from its Medicines and Technologies segment. This represents a decrease from the previous year's €26.85 million. The United Kingdom was the largest contributor to the company's revenue.